AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 26760454 — intervention group
Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 1838
Study 24412053 — intervention group
Group type: EXPERIMENTAL
Intervention: miR-10b
Number of subjects: 60
Study 24412053 — intervention group
Group type: EXPERIMENTAL
Intervention: miR-21
Number of subjects: 60
Study 24412053 — intervention group
Group type: EXPERIMENTAL
Intervention: miR-7
Number of subjects: 60
Study 24412053 — intervention group
Group type: EXPERIMENTAL
Intervention: miR-31
Number of subjects: 60
Study 24412053 — intervention group
Group type: EXPERIMENTAL
Intervention: miR-101
Number of subjects: 60
Study 24412053 — intervention group
Group type: EXPERIMENTAL
Intervention: miR-137
Number of subjects: 60
Study 24412053 — intervention group
Group type: EXPERIMENTAL
Intervention: miR-222
Number of subjects: 60
Study 24412053 — intervention group
Group type: EXPERIMENTAL
Intervention: miR-330
Number of subjects: 60
Study 24412053 — intervention group
Group type: COMPARATOR
Intervention: miR-34a
Number of subjects: 60
Study 21895939 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravesical hyaluronic acid (HA) instillation
Number of subjects: 36
Study 21895939 — intervention group
Group type: COMPARATOR
Intervention: Hyperbaric oxygen (HBO)
Number of subjects: 36
Study 20970847 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (≥75 mg daily)
Number of subjects: 14033
Study 20970847 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (75-300 mg daily)
Number of subjects: 14033
Study 20970847 — intervention group
Group type: COMPARATOR
Intervention: Aspirin (30 mg vs 283 mg daily)
Number of subjects: 14033
Study 17284755 — intervention group
Group type: COMPARATOR
Intervention: Control group: 30 g dry weight of an iron-fortified cereal porridge and a separate dose of an aqueous multivitamin (MV) supplement
Number of subjects: 0
Study 17284755 — intervention group
Group type: EXPERIMENTAL
Intervention: ZnSuppl group: same porridge and MV with 3 mg Zn added to the supplement dose
Number of subjects: 0
Study 17284755 — intervention group
Group type: EXPERIMENTAL
Intervention: ZnFort group: porridge with added zinc (150 mg/kg dry weight) and MV without zinc
Number of subjects: 0
Study 16086129 — intervention group
Group type: EXPERIMENTAL
Intervention: Media-mediated events in elderly healthy people
Number of subjects: 0
Study 16086129 — intervention group
Group type: EXPERIMENTAL
Intervention: Media-mediated events in younger normal subjects
Number of subjects: 0
Study 16086129 — intervention group
Group type: EXPERIMENTAL
Intervention: Normative procedure applied to subjects with probable Alzheimer's disease or mild cognitive impairment
Number of subjects: 0
Study 12212714 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer sexual health intervention (1 hour and 45 minutes)
Number of subjects: 0
Study 12212714 — intervention group
Group type: COMPARATOR
Intervention: Peer water purification intervention (1 hour)
Number of subjects: 0
Study 11531750 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-contrast enhanced helical CT
Number of subjects: 242
Study 11531750 — intervention group
Group type: COMPARATOR
Intervention: Intravenous urography (IVU)
Number of subjects: 242
Study 9049794 — intervention group
Group type: EXPERIMENTAL
Intervention: Braun Oral‐B Plak Control electric toothbrush
Number of subjects: 111
Study 9049794 — intervention group
Group type: COMPARATOR
Intervention: Conventional soft manual toothbrush (Jordan)
Number of subjects: 111
Study 8457038 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide (200 micrograms twice daily for 14 days)
Number of subjects: 30
Study 3469982 — intervention group
Group type: EXPERIMENTAL
Intervention: Prognostic indices (age, blood pressure, white cell count, blood urea, serum calcium, aspartate aminotransferase, lactate dehydrogenase, blood glucose, arterial blood pH and PO2)
Number of subjects: 100
Study 31629353 — intervention group
Group type: EXPERIMENTAL
Intervention: LOW carbohydrate availability during low-intensity training (LIT) sessions
Number of subjects: 11
Study 31629353 — intervention group
Group type: COMPARATOR
Intervention: HIGH carbohydrate availability during low-intensity training (LIT) sessions
Number of subjects: 11
Study 29189275 — intervention group
Group type: EXPERIMENTAL
Intervention: US-assisted LSGB with 10 mL of 0.25% levobupivacaine
Number of subjects: 50
Study 29189275 — intervention group
Group type: COMPARATOR
Intervention: FL-guided LSGB with 10 mL of 0.25% levobupivacaine
Number of subjects: 50
Study 27346859 — intervention group
Group type: EXPERIMENTAL
Intervention: Luteal phase
Number of subjects: 16
Study 27346859 — intervention group
Group type: COMPARATOR
Intervention: Follicular phase
Number of subjects: 16
Study 24717789 — intervention group
Group type: EXPERIMENTAL
Intervention: GSK2190915 200 mg
Number of subjects: 47
Study 24717789 — intervention group
Group type: EXPERIMENTAL
Intervention: GSK2190915 100 mg
Number of subjects: 47
Study 24717789 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study 23685330 — intervention group
Group type: EXPERIMENTAL
Intervention: Cannabidiol (CBD), inhaler used when feeling the urge to smoke
Number of subjects: 24
Study 23685330 — intervention group
Group type: COMPARATOR
Intervention: Placebo, inhaler used when feeling the urge to smoke
Number of subjects: 24
Study 20616088 — intervention group
Group type: EXPERIMENTAL
Intervention: Second cohort signers (acquired language in a more complex form)
Number of subjects: 2
Study 20616088 — intervention group
Group type: EXPERIMENTAL
Intervention: Second cohort signers
Number of subjects: 2
Study 20616088 — intervention group
Group type: COMPARATOR
Intervention: First cohort signers
Number of subjects: 2
Study 20616088 — intervention group
Group type: EXPERIMENTAL
Intervention: Consistent linguistic marking of left-right relations
Number of subjects: 2
Study 20616088 — intervention group
Group type: EXPERIMENTAL
Intervention: Consistent marking of ground information
Number of subjects: 2
Study 18441680 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiotorpium bromide (TB) 18 mcg/day for one year, almitrine 10 mg/kg/day for 3 months, and an 8 week course of pulmonary rehabilitation (PR)
Number of subjects: 39
Study 18441680 — intervention group
Group type: COMPARATOR
Intervention: Thiotorpium bromide (TB) and pulmonary rehabilitation (PR)
Number of subjects: 39
Study 16619217 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual Inspection with Acetic Acid (VIA) by nurses
Number of subjects: 1528
Study 16619217 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual Inspection with Lugol's Iodine (VILI) by nurses
Number of subjects: 1528
Study 16619217 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual Inspection with Acetic Acid (VIA) by physicians
Number of subjects: 1528
Study 16619217 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual Inspection with Lugol's Iodine (VILI) by physicians
Number of subjects: 1528
Study 16619217 — intervention group
Group type: COMPARATOR
Intervention: Pap cytology
Number of subjects: 1528
Study 15029983 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg oral methadone tablet
Number of subjects: 204
Study 15029983 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg sublingual buprenorphine tablet
Number of subjects: 204
Study 15029983 — intervention group
Group type: COMPARATOR
Intervention: 50 mg oral naltrexone
Number of subjects: 204
Study 10966839 — intervention group
Group type: EXPERIMENTAL
Intervention: GP‐C (glycosaminoglycan polypeptide association complex) 2 ml intramuscularly, 10 courses over 5 years (15 injections per course, twice weekly)
Number of subjects: 394
Study 10966839 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 394
Study 10966839 — intervention group
Group type: EXPERIMENTAL
Intervention: GP‐C
Number of subjects: 394
Study 8979741 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.9 km/day (3,000 walking steps/day) (hypokinetic subjects)
Number of subjects: 20
Study 8979741 — intervention group
Group type: COMPARATOR
Intervention: 14.6 km/day (10,000 running steps/day) (control subjects)
Number of subjects: 20
Study 1335393 — intervention group
Group type: EXPERIMENTAL
Intervention: KCl (100 mmol)
Number of subjects: 21
Study 1335393 — intervention group
Group type: COMPARATOR
Intervention: NaCl (100 mmol)
Number of subjects: 21
Study 1335393 — intervention group
Group type: EXPERIMENTAL
Intervention: KCl (0.75 mmol/kg infused over 2 h)
Number of subjects: 21
Study 1335393 — intervention group
Group type: EXPERIMENTAL
Intervention: KHCO3 (1 mmol/kg)
Number of subjects: 21
Study 1335393 — intervention group
Group type: EXPERIMENTAL
Intervention: KCl (1 mmol/kg)
Number of subjects: 21
Study 29713728 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin 10 mg or 25 mg
Number of subjects: 2004
Study 29713728 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2004
Study 29713728 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin
Number of subjects: 2004
Study 26430128 — intervention group
Group type: EXPERIMENTAL
Intervention: Lecture training method
Number of subjects: 128
Study 26430128 — intervention group
Group type: EXPERIMENTAL
Intervention: Paper-based training method
Number of subjects: 128
Study 26430128 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer training method
Number of subjects: 128
Study 26430128 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 128
Study 24581929 — intervention group
Group type: EXPERIMENTAL
Intervention: Absolute frequency and/or percentage information
Number of subjects: 2807
Study 24581929 — intervention group
Group type: EXPERIMENTAL
Intervention: Relative frequency information
Number of subjects: 2807
Study 24581929 — intervention group
Group type: COMPARATOR
Intervention: No efficacy information
Number of subjects: 2807
Study 22051419 — intervention group
Group type: EXPERIMENTAL
Intervention: Levosimendan infusion at a dose of 0.1 μg/kg/min with an initial bolus (12 μg/kg for 10 minutes) after anesthesia induction (Group C)
Number of subjects: 90
Study 22051419 — intervention group
Group type: COMPARATOR
Intervention: Intra-aortic balloon pump (IABP) one day before surgery (Group A)
Number of subjects: 90
Study 22051419 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic IABP one day before surgery and levosimendan infusion (Group B)
Number of subjects: 90
Study 22051419 — intervention group
Group type: COMPARATOR
Intervention: Control group (Group A)
Number of subjects: 90
Study 21138627 — intervention group
Group type: EXPERIMENTAL
Intervention: Without anti-viral therapy (study group)
Number of subjects: 177
Study 21138627 — intervention group
Group type: COMPARATOR
Intervention: Lamivudine therapy (control group)
Number of subjects: 177
Study 18207017 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple micronutrient (MMN) supplementation
Number of subjects: 31290
Study 18207017 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple micronutrient (MMN) supplementation in undernourished women (MUAC <23.5 cm)
Number of subjects: 31290
Study 18207017 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple micronutrient (MMN) supplementation in anaemic women (Hb <110 g/L)
Number of subjects: 31290
Study 18207017 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple micronutrient (MMN) supplementation in undernourished women
Number of subjects: 31290
Study 18207017 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple micronutrient (MMN) supplementation in anaemic women
Number of subjects: 31290
Study 18207017 — intervention group
Group type: COMPARATOR
Intervention: Iron and folic acid (IFA) supplementation
Number of subjects: 31290
Study 15985134 — intervention group
Group type: EXPERIMENTAL
Intervention: L‐aspartate and L‐glutamate-enriched cardioplegia (13 mmol/L)
Number of subjects: 22
Study 15985134 — intervention group
Group type: COMPARATOR
Intervention: Control group (cardioplegia including only potassium and sodium bicarbonate)
Number of subjects: 22
Study 12544752 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcranial electrostimulation (TCES)
Number of subjects: 20
Study 12544752 — intervention group
Group type: COMPARATOR
Intervention: Active placebo device
Number of subjects: 20
Study 10391395 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (250 mg three times daily for 12 months)
Number of subjects: 70
Study 10391395 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study 8683251 — intervention group
Group type: EXPERIMENTAL
Intervention: Melphalan and prednisone (MP)
Number of subjects: 77
Study 8683251 — intervention group
Group type: EXPERIMENTAL
Intervention: Vincristine, cyclophosphamide, melphalan, and prednisone (VCMP) / vincristine, carmustine (BCNU), doxorubicin, and prednisone (VBAP)
Number of subjects: 77
Study 8683251 — intervention group
Group type: COMPARATOR
Intervention: Control group (conventional chemotherapy)
Number of subjects: 77
Study 8683251 — intervention group
Group type: EXPERIMENTAL
Intervention: Early high-dose therapy (HDT)
Number of subjects: 77
Study 1706505 — intervention group
Group type: EXPERIMENTAL
Intervention: DDD pacing
Number of subjects: 60
Study 1706505 — intervention group
Group type: COMPARATOR
Intervention: VVI pacing
Number of subjects: 60
Study 1706505 — intervention group
Group type: COMPARATOR
Intervention: VVI pacing (in crossover study)
Number of subjects: 60
Study 1706505 — intervention group
Group type: COMPARATOR
Intervention: Preimplant predictive value for VVI pacing success
Number of subjects: 60
Study 1706505 — intervention group
Group type: COMPARATOR
Intervention: Preimplant predictive value for VVI pacing failure
Number of subjects: 60
Study 6144125 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol 1 mg, 3 mg, and 6 mg
Number of subjects: 0
Study 6144125 — intervention group
Group type: EXPERIMENTAL
Intervention: Propericiazine 10 mg and 30 mg
Number of subjects: 0
Study 6144125 — intervention group
Group type: EXPERIMENTAL
Intervention: Propericiazine 60 mg
Number of subjects: 0
Study 6144125 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30681754 — intervention group
Group type: EXPERIMENTAL
Intervention: Opicapone 25 mg
Number of subjects: 0
Study 30681754 — intervention group
Group type: EXPERIMENTAL
Intervention: Opicapone 50 mg
Number of subjects: 0
Study 30681754 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30681754 — intervention group
Group type: EXPERIMENTAL
Intervention: Opicapone 50 mg (open-label phase)
Number of subjects: 0
Study 30681754 — intervention group
Group type: COMPARATOR
Intervention: Switching from placebo to opicapone
Number of subjects: 0
Study 30383670 — intervention group
Group type: EXPERIMENTAL
Intervention: Microecological preparation supplementation
Number of subjects: 0
Study 27174665 — intervention group
Group type: EXPERIMENTAL
Intervention: Carescapes intervention
Number of subjects: 310
Study 27174665 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 310
Study 25036712 — intervention group
Group type: COMPARATOR
Intervention: Sham surgery
Number of subjects: 0
Study 25036712 — intervention group
Group type: EXPERIMENTAL
Intervention: Open-label levodopa treatment
Number of subjects: 0
Study 25036712 — intervention group
Group type: EXPERIMENTAL
Intervention: Monte Carlo simulations
Number of subjects: 0
Study 22933023 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypoxia (Fi(O2) = 0.13)
Number of subjects: 6
Study 22933023 — intervention group
Group type: COMPARATOR
Intervention: Normoxia (NOR)
Number of subjects: 6
Study 20153684 — intervention group
Group type: EXPERIMENTAL
Intervention: Carboxymethylcellulose sodium (CMC), 0.5% (Cellufresh)
Number of subjects: 60
Study 20153684 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyethylene glycol 400, 2.5% and sodium hyaluronate (Blink Intensive Tears)
Number of subjects: 60
Study 20153684 — intervention group
Group type: EXPERIMENTAL
Intervention: HP Guar 0.18% (Systane)
Number of subjects: 60
Study 20153684 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 60
Study 17216895 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral interventions (CBIs) - music
Number of subjects: 324
Study 17216895 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral interventions (CBIs) - kaleidoscope
Number of subjects: 324
Study 17216895 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral interventions (CBIs) - guided imagery
Number of subjects: 324
Study 17216895 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 324
Study 12614797 — intervention group
Group type: EXPERIMENTAL
Intervention: Stented Perimount bioprosthesis (n=20)
Number of subjects: 40
Study 12614797 — intervention group
Group type: COMPARATOR
Intervention: Stentless Prima Plus bioprosthesis (n=20)
Number of subjects: 40
Study 12614797 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (stented and stentless)
Number of subjects: 40
Study 10869576 — intervention group
Group type: COMPARATOR
Intervention: Forced-choice recognition test
Number of subjects: 0
Study 10869576 — intervention group
Group type: COMPARATOR
Intervention: Yes-no recognition test
Number of subjects: 0
Study 10869576 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy subjects
Number of subjects: 0
Study 9199818 — intervention group
Group type: EXPERIMENTAL
Intervention: rt-PA, 100 mg over 2 h (Group A)
Number of subjects: 47
Study 9199818 — intervention group
Group type: COMPARATOR
Intervention: rt-PA, 0.6 mg/kg, maximum dose 50 mg, over 15 min (Group B)
Number of subjects: 47
Study 9199818 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 47
Study 1350485 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol 50 mg
Number of subjects: 0
Study 1350485 — intervention group
Group type: COMPARATOR
Intervention: Metoprolol 200 mg
Number of subjects: 0
Study 3900392 — intervention group
Group type: EXPERIMENTAL
Intervention: Amflutizole 500 mg dosage
Number of subjects: 29
Study 31630511 — intervention group
Group type: EXPERIMENTAL
Intervention: Whey Protein Nutritional Drink (WPND)
Number of subjects: 19
Study 31630511 — intervention group
Group type: COMPARATOR
Intervention: Apple Juice (AJ)
Number of subjects: 19
Study 31131629 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended-release niacin (ERN)
Number of subjects: 3196
Study 31131629 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3196
Study 28842727 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose vitamin D3 (loading dose of 540,000 IU and five monthly maintenance doses of 90,000 IU)
Number of subjects: 289
Study 28842727 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 289
Study 28842727 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose vitamin D3
Number of subjects: 289
Study 25813216 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocodone ER 15 mg
Number of subjects: 60
Study 25813216 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocodone ER 30 mg
Number of subjects: 60
Study 25813216 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocodone ER 45 mg
Number of subjects: 60
Study 25813216 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocodone ER 60 mg
Number of subjects: 60
Study 25813216 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocodone ER 90 mg
Number of subjects: 60
Study 25813216 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocodone ER (all doses)
Number of subjects: 60
Study 25813216 — intervention group
Group type: COMPARATOR
Intervention: Naltrexone (used to minimize AEs)
Number of subjects: 60
Study 23648145 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes
Number of subjects: 1250
Study 23648145 — intervention group
Group type: COMPARATOR
Intervention: No diabetes
Number of subjects: 1250
Study 21266203 — intervention group
Group type: EXPERIMENTAL
Intervention: Progression-free survival (PFS)
Number of subjects: 70
Study 21266203 — intervention group
Group type: EXPERIMENTAL
Intervention: Percentage change in tumor burden (dTB)
Number of subjects: 70
Study 21266203 — intervention group
Group type: COMPARATOR
Intervention: PFS
Number of subjects: 70
Study 21266203 — intervention group
Group type: COMPARATOR
Intervention: dTB
Number of subjects: 70
Study 19681859 — intervention group
Group type: EXPERIMENTAL
Intervention: Tretinoin 0.1% cream
Number of subjects: 736
Study 19681859 — intervention group
Group type: COMPARATOR
Intervention: Vehicle control cream
Number of subjects: 736
Study 17279096 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical phenytoin solution (5 mg/ml)
Number of subjects: 28
Study 17279096 — intervention group
Group type: COMPARATOR
Intervention: Normal saline dressing
Number of subjects: 28
Study 15476909 — intervention group
Group type: EXPERIMENTAL
Intervention: Subhypnotic-dose propofol 1.0 mg/kg per hour combined with dexamethasone 8 mg
Number of subjects: 120
Study 15476909 — intervention group
Group type: COMPARATOR
Intervention: Subhypnotic-dose propofol 1.0 mg/kg per hour alone
Number of subjects: 120
Study 12204495 — intervention group
Group type: EXPERIMENTAL
Intervention: Tirofiban (T)
Number of subjects: 0
Study 12204495 — intervention group
Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 0
Study 9695162 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg pseudoephedrine
Number of subjects: 40
Study 9695162 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 8605519 — intervention group
Group type: EXPERIMENTAL
Intervention: 6% glucose/sucrose solution
Number of subjects: 7
Study 8605519 — intervention group
Group type: COMPARATOR
Intervention: Placebo (artificially flavored and sweetened solution)
Number of subjects: 7
Study 2663585 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibopamine 100 mg t.i.d.
Number of subjects: 97
Study 2663585 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 97
Study 821050 — intervention group
Group type: EXPERIMENTAL
Intervention: Cooling treatment with 'Cryogel'
Number of subjects: 0
Study 821050 — intervention group
Group type: COMPARATOR
Intervention: Crepe bandaging
Number of subjects: 0
Study 31145344 — intervention group
Group type: EXPERIMENTAL
Intervention: Torsional and burst mode phacoemulsification (Group B, n = 40)
Number of subjects: 80
Study 31145344 — intervention group
Group type: COMPARATOR
Intervention: Conventional mode phacoemulsification (Group A, n = 40)
Number of subjects: 80
Study 31145344 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (A and B)
Number of subjects: 80
Study 28576892 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional and complementary medicine interventions (ear and body acupuncture, aromatherapy) in combination with nicotine replacement therapy (NRT) and counselling
Number of subjects: 40
Study 28576892 — intervention group
Group type: COMPARATOR
Intervention: Conventional cessation methods (nicotine replacement therapy (NRT), counselling)
Number of subjects: 40